Novostia is a pre-revenue, private medical device innovator based in Lausanne, Switzerland, focused on addressing significant unmet needs in cardiovascular valve replacement. Its core product, the Triflo valve, is a novel artificial heart valve engineered to combine durability, reduced blood clot risk, and quiet operation, aiming to serve patients of all ages, including children. The company is in the late preclinical stage, supported by EU Horizon 2020 funding and academic collaborations, and is preparing for first-in-human clinical trials.
Cardiovascular
Technology Platform
Novel artificial heart valve design focused on low thrombogenicity, lifelong durability, and low acoustic signature, leveraging interdisciplinary engineering from aeronautics and fluid dynamics.
Funding History
2
Total raised:$17.1M
Series A$15MSwisscanto Invest
Grant$2.1MInnosuisse
Opportunities
Addressing a large unmet need for durable, anticoagulant-free heart valves in younger and pediatric patients, a segment poorly served by current mechanical and bioprosthetic options.
The global valvular heart disease market is vast and growing, with over 100 million patients, providing a significant addressable market for a disruptive technology.
Risk Factors
High clinical and regulatory risk as the investigational device has not yet been tested in humans.
Significant financing risk to fund expensive pivotal trials, and intense competition from large, established medical device companies with substantial R&D and commercial capabilities.
Competitive Landscape
The heart valve market is dominated by large players like Edwards Lifesciences, Abbott, and Medtronic, who offer both mechanical and tissue valves and are continuously innovating. Novostia's potential differentiation lies in combining the durability of mechanical valves with the low thrombogenicity of tissue valves, a niche currently unoccupied by major competitors.
